Meda has signed an agreement to acquire Valeant’s pharmaceutical business in western and eastern Europe. The acquisition will give Meda an entry into the Russian market. In Eastern Europe, it means a potential for significant market synergies with products in Meda’s existing pipeline, according to the company. In western Europe, Meda’s position will be strengthened, especially in the UK. The majority of the acquired products are also within Meda’s key therapy areas; neurology and dermatology, in...